Behbahani Ali — SEC Form 4 filings
SEC reporting owner CIK 1613867. 44 Form 4 filings on record with FilingPulse; latest filed 2026-07-06.
Transaction summary — filings shown
Covers all 44 filings on record, filed 2024-01-17 to 2026-07-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 3 filings — 1,991,750 shares, $24,773,600 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 6 legs across 2 filings — 19,503,915 shares, $255,598 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 94.
- Largest priced transaction: purchase of 937,500 shares @ $16.00 ($15,000,000) in SpyGlass Pharma, Inc., filed 2026-02-11.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| SpyGlass Pharma, Inc. (SGP) | Director, 10% owner | 2 | 1 leg · 937,500 sh · $15,000,000 | — | 13 |
| MBX Biosciences, Inc. (MBX) | 10% owner | 1 | 1 leg · 500,000 sh · $8,000,000 | — | 4 |
| Marker Therapeutics, Inc. (MRKR) | 10% owner | 1 | 1 leg · 554,250 sh · $1,773,600 | — | — |
| Adaptimmune Therapeutics PLC (ADAP) | Director | 3 | — | 2 legs · 19,500,000 sh · $229,172 | 2 |
| NeueHealth, Inc. (NEUE) | Director, 10% owner | 3 | — | 4 legs · 3,915 sh · $26,426 | 33 |
| Black Diamond Therapeutics, Inc. (BDTX) | Director | 13 | — | — | 13 |
| Arcellx, Inc. (ACLX) | Director | 4 | — | — | 9 |
| Korro Bio, Inc. (KRRO) | Director | 5 | — | — | 6 |
| Monte Rosa Therapeutics, Inc. (GLUE) | Director | 4 | — | — | 6 |
| CRISPR Therapeutics AG (CRSP) | Director | 3 | — | — | 3 |
+2 more issuers among the filings shown — every filing appears in the table below.
Form 4 filings — Behbahani Ali
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-06 | 4 | Monte Rosa Therapeutics, Inc. (GLUE) | Other (J): 1,000,000 @ $0 · Other (J): 15,000 @ $0 · Other (J): 15,000 @ $0 | EDGAR |
| 2026-06-29 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 8,961 @ $1.66 | EDGAR |
| 2026-06-12 | 4 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/award (A): 25,800 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 37,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Korro Bio, Inc. (KRRO) | Grant/award (A): 14,677 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2026-04-28 | 4 | Arcellx, Inc. (ACLX) | Code (U): 1,925 · Code (U): 2,706 · Disposition to issuer (D): 11,459 (derivative) · Disposition to issuer (D): 8,011 (derivative) · Disposition to issuer (D): 9,174 (derivative) | EDGAR |
| 2026-03-20 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 6,919 @ $2.15 | EDGAR |
| 2026-03-12 | 4 | Korro Bio, Inc. (KRRO) | Grant/award (A): 207,100 @ $11.11 · Grant/award (A): 242,945 (derivative) @ $11.11 | EDGAR |
| 2026-02-11 | 4 | SpyGlass Pharma, Inc. (SGP) | Conversion (C): 1,619,240 · Conversion (C): 1,370,168 · Conversion (C): 1,370,168 · Conversion (C): 737,962 · Purchase (P): 937,500 @ $16 · Conversion (C): 954,990 · +7 more | EDGAR |
| 2026-02-09 | 4 | SpyGlass Pharma, Inc. (SGP) | Grant/award (A): 27,400 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 5,208 @ $2.76 | EDGAR |
| 2025-10-06 | 4 | NeueHealth, Inc. (NEUE) | Option exercise/expiry (X): 189,195 @ $0.01 · Sale (S): 280 @ $6.75 · Option exercise (M): 372,255 @ $0.01 · Tax withholding (F): 551 @ $6.75 · Disposition to issuer (D): 1,159,683 · Option exercise/expiry (X): 189,195 @ $0.01 · +25 more | EDGAR |
| 2025-09-22 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 4,291 @ $3.35 | EDGAR |
| 2025-08-19 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Sale (S): 4,828,206 @ $0.01 · Sale (S): 14,671,794 @ $0.01 | EDGAR |
| 2025-08-14 | 4 | Arcellx, Inc. (ACLX) | Other (J): 1,586 @ $0 · Other (J): 2,621 @ $0 | EDGAR |
| 2025-06-20 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 6,170 @ $2.33 | EDGAR |
| 2025-06-16 | 4 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/award (A): 30,700 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Korro Bio, Inc. (KRRO) | Grant/award (A): 6,010 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 30,550 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 46,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2025-05-30 | 4 | Arcellx, Inc. (ACLX) | Grant/award (A): 9,174 (derivative) @ $0 | EDGAR |
| 2025-03-21 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 7,646 @ $1.88 | EDGAR |
| 2024-12-23 | 4 | Marker Therapeutics, Inc. (MRKR) jointly with New Enterprise Associates 16, L.P., NEA Partners 16, L.P., NEA 16 GP, LLC, BASKETT FOREST, Chang Carmen, Florence Anthony A. Jr., Makhzoumi Mohamad, SANDELL SCOTT D, Walker Paul Edward | Purchase (P): 554,250 @ $3.20 | EDGAR |
| 2024-12-16 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 5,750 @ $2.50 | EDGAR |
| 2024-10-03 | 4 | NeueHealth, Inc. (NEUE) | Purchase (P): 61,865 (derivative) · Purchase (P): 61,865 (derivative) · Purchase (P): 185,595 (derivative) | EDGAR |
| 2024-09-20 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 3,007 @ $4.78 | EDGAR |
| 2024-09-17 | 4 | MBX Biosciences, Inc. (MBX) | Conversion (C): 1,023,103 · Conversion (C): 2,091,383 · Purchase (P): 500,000 @ $16 · Conversion (C): 12,299,854 (derivative) · Conversion (C): 25,142,840 (derivative) | EDGAR |
| 2024-07-01 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 1,144,686 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 2,887 @ $4.98 | EDGAR |
| 2024-06-14 | 4 | Nkarta, Inc. (NKTX) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Monte Rosa Therapeutics, Inc. (GLUE) | Grant/award (A): 22,100 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | Korro Bio, Inc. (KRRO) | Grant/award (A): 5,190 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4/A | CVRx, Inc. (CVRX) | Grant/award (A): 27,250 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | CVRx, Inc. (CVRX) | Grant/award (A): 20,961 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Arcellx, Inc. (ACLX) | Grant/award (A): 8,011 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 30,550 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | CRISPR Therapeutics AG (CRSP) | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2024-04-24 | 4 | Korro Bio, Inc. (KRRO) | Grant/award (A): 17,857 @ $56 | EDGAR |
| 2024-04-10 | 4 | NeueHealth, Inc. (NEUE) | Purchase (P): 123,729 (derivative) · Purchase (P): 123,729 (derivative) · Purchase (P): 371,187 (derivative) | EDGAR |
| 2024-04-03 | 4 | Black Diamond Therapeutics, Inc. (BDTX) | Grant/award (A): 3,166 @ $4.54 | EDGAR |
| 2024-01-17 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 40,950 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1613867 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →